Sjögren's syndrome medical therapy

Revision as of 20:20, 2 April 2018 by Farima Kahe (talk | contribs)
Jump to navigation Jump to search

Sjögren's syndrome Microchapters

Home

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Sjögren's syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

Echocardiography and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Sjögren's syndrome medical therapy On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Sjögren's syndrome medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Sjögren's syndrome medical therapy

CDC on Sjögren's syndrome medical therapy

Sjögren's syndrome medical therapy in the news

Blogs on Sjögren's syndrome medical therapy

Directions to Hospitals Treating Sjögren's syndrome

Risk calculators and risk factors for Sjögren's syndrome medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Farima Kahe M.D. [2]

Overview

Medical Therapy

  • Dry eye, dry mouth, and other sicca symptoms:
    • Preferred regimen (1): Pilocarpine 5 mg PO q8h
    • Preferred regimen (2): Cevimeline 30 mg PO q8h
  • Organ-based disease and constitutional symptoms:
    • Preferred regimen (1): Hydroxychloroquine 5 mg PO q8h
    • Preferred regimen (2): Methotrexate 30 mg PO q8h
    • Preferred regimen (2): Leflunomide 30 mg PO q8h
    • Preferred regimen (2): Azathioprine 30 mg PO q8h
    • Preferred regimen (2): Sulfasalazine 30 mg PO q8h
    • Preferred regimen (2): Cyclosporine 30 mg PO q8h
    • Preferred regimen (2): Cyclophosphamide 30 mg PO q8h
    • Preferred regimen (2): Rituximab 30 mg PO q8h

References

Template:WH Template:WS